Company Overview of Melinta Therapeutics, Inc.
Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.
300 George Street
New Haven, CT 06511-6663
Founded in 2000
Key Executives for Melinta Therapeutics, Inc.
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2014.
Melinta Therapeutics, Inc. Key Developments
Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A
Jan 12 15
Melinta Therapeutics, Inc. and Eurofarma Laboratorios S.A. have entered into commercialization and distribution agreements for delafloxacin, an investigational fluoroquinolone. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta will receive a combined upfront cash and equity payment of $15 million, as well as milestones and royalties on future sales of delafloxacin.
Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV
Jan 8 15
Ligand Pharmaceuticals Incorporated announced that its partner Melinta Therapeutics reported positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to evaluate delafloxacin, an investigational fluoroquinolone, compared with vancomycin + aztreonam for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin met the study' s primary objective endpoint of a reduction in the measurement of lesion erythema at the primary infection site at 48- to- 72 hours, the endpoint required by the U.S. Food and Drug Administration (FDA). Delafloxacin also was comparable to vancomycin in the studyâ s secondary endpoints, including investigator assessment of signs and symptoms of infection at the follow-up visit, a metric required by the European Medicines Agency (EMA). Melinta reports that delafloxacin was shown to be well tolerated among study participants. Mild gastrointestinal symptoms were the most common treatment-related adverse events reported for delafloxacin, and rarely led to study discontinuation. Melinta expects to make complete results from this study available as a presentation at an upcoming medical meeting and a publication in a peer-reviewed medical journal.
Melinta Therapeutics and Hartford Hospital Announces Vitro Results from an Investigator-Sponsored Study
Sep 6 14
Melinta Therapeutics and Hartford Hospital announced in vitro results from an investigator-sponsored study that highlight delafloxacin's activity in low pH environments, which are characteristic of infection sites. Delafloxacin is an investigational fluoroquinolone under development for acute bacterial skin and skin structure infections and uncomplicated gonorrhea. In this study, which was conducted by Drs. Wonhee So, Jared Crandon and David Nicolau in the Center for Anti-Infective Research and Development at Hartford Hospital, urine samples were collected from patients suspected of having a urinary tract infection (UTI). Greater than 70% of these samples were acidic, with pH measured at or below 6.5. In all patient samples tested, delafloxacin was shown to be active against Escherichia coli and Klebsiella pneumoniae, two pathogens that are frequently associated with complicated UTIs. Importantly, in the acidic samples (pH 5.0-6.0), delafloxacin's activity was found to be one to threefold greater than in normal or basic samples. Complete results from this study are being presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5, 2014 - September 9, 2014 at the Walter E. Washington Convention Center in Washington, DC.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 8, 2015
December 31, 2014